Literature DB >> 11160754

Epstein-Barr virus nuclear protein 2 has at least two N-terminal domains that mediate self-association.

S Harada1, R Yalamanchili, E Kieff.   

Abstract

Previous genetic and biochemical analyses have indicated that the Epstein-Barr virus EBNA-2 amino terminus is important for primary B-lymphocyte growth transformation and may be involved in self-association. We now report that EBNA-2 has at least two domains, amino acids 1 to 60 and 96 to 210, which independently mediate homotypic association, 1 to 60 with 1 to 60 and 96 to 210 with 96 to 210. EBNA-2 self-association is likely to be critical to the ability of EBNA-2 to interact simultaneously with multiple cellular transcription factors, coactivators, and histone acetyltransferases through its RBPJkappa binding and acidic activating domains.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11160754      PMCID: PMC114834          DOI: 10.1128/JVI.75.5.2482-2487.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

1.  The N-terminal half of EBNA2, except for seven prolines, is not essential for primary B-lymphocyte growth transformation.

Authors:  R Yalamanchili; S Harada; E Kieff
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

Review 2.  Developments in expression cloning.

Authors:  B Seed
Journal:  Curr Opin Biotechnol       Date:  1995-10       Impact factor: 9.740

3.  Analyzing protein-protein interactions using two-hybrid system.

Authors:  P L Bartel; S Fields
Journal:  Methods Enzymol       Date:  1995       Impact factor: 1.600

4.  The Epstein-Barr virus nuclear protein 2 acidic domain forms a complex with a novel cellular coactivator that can interact with TFIIE.

Authors:  X Tong; R Drapkin; R Yalamanchili; G Mosialos; E Kieff
Journal:  Mol Cell Biol       Date:  1995-09       Impact factor: 4.272

5.  The Epstein-Barr virus nuclear protein 2 acidic domain can interact with TFIIB, TAF40, and RPA70 but not with TATA-binding protein.

Authors:  X Tong; F Wang; C J Thut; E Kieff
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

6.  An ATF/CRE element mediates both EBNA2-dependent and EBNA2-independent activation of the Epstein-Barr virus LMP1 gene promoter.

Authors:  A Sjöblom; W Yang; L Palmqvist; A Jansson; L Rymo
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

7.  The EVES motif mediates both intermolecular and intramolecular regulation of c-Myb.

Authors:  A B Dash; F C Orrico; S A Ness
Journal:  Genes Dev       Date:  1996-08-01       Impact factor: 11.361

8.  Epstein-Barr virus leader protein enhances EBNA-2-mediated transactivation of latent membrane protein 1 expression: a role for the W1W2 repeat domain.

Authors:  F Nitsche; A Bell; A Rickinson
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

9.  Epstein-Barr virus nuclear protein LP stimulates EBNA-2 acidic domain-mediated transcriptional activation.

Authors:  S Harada; E Kieff
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

10.  The Spi-1/PU.1 and Spi-B ets family transcription factors and the recombination signal binding protein RBP-J kappa interact with an Epstein-Barr virus nuclear antigen 2 responsive cis-element.

Authors:  G Laux; B Adam; L J Strobl; F Moreau-Gachelin
Journal:  EMBO J       Date:  1994-12-01       Impact factor: 11.598

View more
  14 in total

1.  Conserved region CR2 of Epstein-Barr virus nuclear antigen leader protein is a multifunctional domain that mediates self-association as well as nuclear localization and nuclear matrix association.

Authors:  Michiko Tanaka; Akihiko Yokoyama; Mie Igarashi; Go Matsuda; Kentaro Kato; Mikiko Kanamori; Kanji Hirai; Yasushi Kawaguchi; Yuji Yamanashi
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

2.  EBNA2 amino acids 3 to 30 are required for induction of LMP-1 and immortalization maintenance.

Authors:  Alexey V Gordadze; Chisaroka W Onunwor; RongSheng Peng; David Poston; Elisabeth Kremmer; Paul D Ling
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

3.  Four EBNA2 domains are important for EBNALP coactivation.

Authors:  Chih-Wen Peng; Bo Zhao; Elliott Kieff
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

4.  Asymmetric Arginine dimethylation of Epstein-Barr virus nuclear antigen 2 promotes DNA targeting.

Authors:  Henrik Gross; Stephanie Barth; Richard D Palermo; Alfredo Mamiani; Christine Hennard; Ursula Zimber-Strobl; Michelle J West; Elisabeth Kremmer; Friedrich A Grässer
Journal:  Virology       Date:  2009-12-06       Impact factor: 3.616

5.  Protein kinase A associates with HA95 and affects transcriptional coactivation by Epstein-Barr virus nuclear proteins.

Authors:  Innoc Han; Yong Xue; Shizuko Harada; Sigurd Orstavik; Bjorn Skalhegg; Elliott Kieff
Journal:  Mol Cell Biol       Date:  2002-04       Impact factor: 4.272

6.  Epstein-Barr virus nuclear antigen 3C putative repression domain mediates coactivation of the LMP1 promoter with EBNA-2.

Authors:  Jeffrey Lin; Eric Johannsen; Erle Robertson; Elliott Kieff
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

7.  Transcription factor RBPJ/CSL: a genome-wide look at transcriptional regulation.

Authors:  Lucio Miele
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-24       Impact factor: 11.205

8.  The EBNA2 polyproline region is dispensable for Epstein-Barr virus-mediated immortalization maintenance.

Authors:  Alexey V Gordadze; David Poston; Paul D Ling
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

9.  EBNA3A association with RBP-Jkappa down-regulates c-myc and Epstein-Barr virus-transformed lymphoblast growth.

Authors:  Andrew Cooper; Eric Johannsen; Seiji Maruo; Ellen Cahir-McFarland; Diego Illanes; David Davidson; Elliott Kieff
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

10.  C-terminal region of EBNA-2 determines the superior transforming ability of type 1 Epstein-Barr virus by enhanced gene regulation of LMP-1 and CXCR7.

Authors:  Laila Cancian; Rachel Bosshard; Walter Lucchesi; Claudio Elgueta Karstegl; Paul J Farrell
Journal:  PLoS Pathog       Date:  2011-07-28       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.